User profiles for Virginia Pascual-Ramos
 | Virginia PascualFounding Director, Drukier Institute for Children's Health at Weill Cornell Medicine Verified email at med.cornell.edu Cited by 40323 |
A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active …
…, S Krishnaswami, V Pascual‐Ramos… - Arthritis & …, 2012 - Wiley Online Library
Objective To compare the efficacy, safety, and tolerability of 6 dosages of oral tofacitinib (CP‐690,550)
with placebo for the treatment of active rheumatoid arthritis (RA) in patients …
with placebo for the treatment of active rheumatoid arthritis (RA) in patients …
Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis
Objectives Patients with rheumatoid arthritis (RA) have an excess risk of cardiovascular
disease (CVD). We aimed to assess the impact of CVD risk factors, including potential sex …
disease (CVD). We aimed to assess the impact of CVD risk factors, including potential sex …
Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries
…, PH Dessein, C Hitchon, V Pascual-Ramos… - …, 2017 - academic.oup.com
Objectives Cardiovascular disease (CVD) risk calculators developed for the general
population do not accurately predict CVD events in patients with RA. We sought to externally …
population do not accurately predict CVD events in patients with RA. We sought to externally …
Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic …
…, J Cabiedes, M Rull-Gabayet, V Pascual-Ramos… - The American journal of …, 2010 - Elsevier
Objectives (1) To determine 6-month follow-up adherence and persistence with disease-modifying
antirheumatic drugs in patients with early rheumatoid arthritis with disease under …
antirheumatic drugs in patients with early rheumatoid arthritis with disease under …
[HTML][HTML] Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and …
V Pascual-Ramos, I Contreras-Yáñez, AR Villa… - Arthritis research & …, 2009 - Springer
Introduction Aggressive treatment with disease-modifying antirheumatic drugs (DMARDs)
plays a major role in improving early rheumatoid arthritis (RA) patient outcomes. Persistence …
plays a major role in improving early rheumatoid arthritis (RA) patient outcomes. Persistence …
Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic, and safety outcomes from a twenty‐four–month, phase …
…, ACC Melazzi, V Pascual‐Ramos… - Arthritis & …, 2019 - Wiley Online Library
Objective Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis ( RA ).
The phase III , 24‐month, placebo‐controlled Oral Rheumatoid Arthritis ( ORAL ) Scan trial …
The phase III , 24‐month, placebo‐controlled Oral Rheumatoid Arthritis ( ORAL ) Scan trial …
Systemic lupus erythematosus as a cause and prognostic factor of acute pancreatitis.
V Pascual-Ramos, A Duarte-Rojo, AR Villa… - The Journal of …, 2004 - jrheum.org
OBJECTIVE: To perform a systematic analysis and case-control study of our patients with
systemic lupus erythematosus (SLE) to determine the prevalence of acute pancreatitis (AP). …
systemic lupus erythematosus (SLE) to determine the prevalence of acute pancreatitis (AP). …
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL …
AR Balanescu, G Citera, V Pascual-Ramos… - Annals of the …, 2022 - ard.bmj.com
Objectives To characterise infections in patients with rheumatoid arthritis (RA) in ORAL
Surveillance. Methods In this open-label, randomised controlled trial, patients with RA aged≥50 …
Surveillance. Methods In this open-label, randomised controlled trial, patients with RA aged≥50 …
Sensorineural Hearing Loss-A Common Finding in Early-Onset Type 2 Diabetes Me Llitus
…, M Osornio, AR Escobedo, V Pascual-Ramos… - Endocrine Practice, 2012 - Elsevier
Objective To evaluate the prevalence and potential associations of hearing impairment in
patients 30 to 50 years old with diabetes diagnosed before age 40 years— early-onset type 2 …
patients 30 to 50 years old with diabetes diagnosed before age 40 years— early-onset type 2 …
Features associated with hematologic abnormalities and their impact in patients with systemic lupus erythematosus: Data from a multiethnic Latin American cohort
…, G Reyes-Llerena, V Pascual-Ramos… - Seminars in Arthritis and …, 2016 - Elsevier
Objective To examine hematological manifestations’ correlates and their impact on damage
accrual and mortality in SLE patients from the multiethnic, Latin American, GLADEL cohort. …
accrual and mortality in SLE patients from the multiethnic, Latin American, GLADEL cohort. …